Publication

Article

Oncology Live®
December 2010
Volume 11
Issue 12

NCCN Launches Consumer-Friendly Versions

Author(s):

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months. The not-for-profit alliance of leading cancer centers designed the publications as consumer-friendly translations of the organization’s vaunted clinical practice guidelines for oncologists. The NCCN Guidelines for Patients, which can be downloaded, feature “decision trees” that explain treatment options from initial detection throughout the course of the disease. The information is presented in a step-by-step manner intended to help patients discuss their options with their healthcare team.

The Susan G. Komen for the Cure foundation provided a $160,000 grant to help develop and distribute guidelines for breast cancer. The patient guidelines for lung cancer are named in honor of Dana Reeve, who died of lung cancer in 2006, 7 months after her diagnosis. She is the wife of the late actor Christopher Reeve.

By early 2011, the NCCN plans to release patient guidelines on melanoma, non-Hodgkin lymphoma, and colon and prostate cancers. Eventually, the group plans to produce such guidelines on all major adult cancers, More Info» www.NCCN.com

Related Videos
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Nicolas Girard, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Shirish M. Gadgeel, MD
Cynthia X. Ma, MD, PhD
Jacob Sands, MD
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Ann H. Partridge, MD, MPH